Translational & Precision Medicine (TPM) Network

Network Goals

Scientific Expertise:

The Translational & Precision Medicine (TPM) Network and associated Communities facilitate interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.

Catalyst for Innovation:

The TPM Network is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on translational and precision medicine.

Influence and Impact:

The TPM Network is the lead group engaged in translational and precision medicine and optimal pharmacotherapy in patient care.

Education and Communication:

The TPM Network offers educational opportunities via the Communities.

Organizational Effectiveness:

Leadership within TPM is expanded by a Network Steering Committee.
The TPM Network has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
The TPM Network fosters the career of its members by assisting Communities in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programming in translational and precision medicine, and providing opportunities for networking activities throughout an individual’s career.

ASCPT Members-Only Webinar presented by the Special Populations Community
Title:Oral Drug Absorption in Pediatrics: What Do We Know and Where Are We Going?
Date and Time: Friday, November 15, 2019, 11:00 am ET
Speakers: Hannah Batchelor, PhD, and Trevor Johnson, PhD
Moderator: Farzaneh Salem, PharmD, PhD
Description: Oral administration is the most common and perhaps the most acceptable route of administration, especially in pediatrics. The therapeutic agent is required to pass the gastrointestinal barrier to exert systemic effects. Age-related physiological and anatomical differences between pediatrics and adults that could potentially impact oral absorption are well-known. However, it is less understood how and to what extent these differences and their variability will affect the systemic exposure and bioavailability of drugs and how this knowledge can be translated into modelling and simulation to enhance our understanding of oral drug absorption. A sound understanding of the interplay between underlying mechanisms of dissolution, permeation and metabolism are required for optimizing absorption and pharmacotherapy in this population. This presentation will include:

Comparison of physiological, biochemical and other differences relevant to pharmacokinetics (PK) and formulations in pediatrics
Potential role of modeling and simulations (including PBPK modeling) in improving our understanding of absorption and dose optimization in this population.

Registration Link: https://attendee.gotowebinar.com/register/8254151839255097857

ASCPT Members-Only Webinar presented by the Special Populations Community
Title: Recent Advances in Neonatal Clinical Pharmacology
Date and Time: Wednesday, December 11, 2019, 11:00 am ET
Speakers and Panelists: David Taft, PhD, and Khaled Abduljalil, PhD
Moderator: Farzaneh Salem, PharmD, PhD
Description: Neonates are one of the most challenging groups of patients when optimizing pharmacotherapy. This is partially due to the rapid physiological and maturational changes that occur in this population, as well as our limited knowledge of the impact of these changes on the pharmacokinetics and pharmacodynamics of drugs in neonates. Prematurity adds another layer of complexity. Clinical trials are seldom performed to establish appropriate dosing in this population. Modeling and simulation techniques and, more recently, physiologically based pharmacokinetic (PBPK) modeling have opened new prospects in the clinical management and dose selection for neonates. The major advances and challenges in modeling and simulations that enable prediction of pharmacokinetic and pharmacodynamics in neonates will be presented in this webinar. This presentation will include an overview of physiological changes in preterm neonates required to develop a PBPK model for preterm population as well as application of preterm PBPK models to predict pharmacokinetics and pharmacodynamics. Discussion will include the potential role of modeling and simulations in improving our understanding and dose optimization in this population. Lastly, a case study will be presented with the antibiotic medication gentamicin that illustrates how PBPK modeling can provide practitioners with a scientific rationale for dosage regimen selection in preterms, thereby promoting safe and effective therapeutic interventions in this patient population.
Registration Link: https://attendee.gotowebinar.com/register/3777513336509565441

ASCPT Members-Only Webinar presented by the Infectious Diseases (INF) Community
Title: Clinical Pharmacology and Modeling and Simulation Applications in Neglected and/or Tropical Diseases
Date and Time: Wednesday, February 5, 2020, 1:00 pm ET
Speakers: Melanie Nicol, PharmD, PhD, and Luning (Ada) Zhuang, PhD
Moderators: Philip Sabato, MSc, PharmD
Description: This presentation will focus on applications and obstacles to clinical pharmacology research in tropical and neglected diseases. The unique opportunities and limitations to clinical pharmacology research in a resource limited setting will be discussed. Additionally, examples of drug repurposing to address neglected diseases and how clinical pharmacology can support these initiatives will be explored. A focus of the second speaker will be on Chagas disease- a neglected, tropical disease. Efficacy and safety data will be shared to provide context of dose recommendations in pediatric patients with Chagas Disease based on a model-informed approach.
Registration Link: https://attendee.gotowebinar.com/register/9102652659409169921